Skip to main content

Nationwide Class Over Elmiron Vision Monitoring Cases Denied

Nationwide Class Over Elmiron Vision Monitoring Cases Denied

Nationwide Class Over Elmiron Vision Monitoring Cases Denied

Introduction

Earlier this month, U.S. District Judge Wendy Beetlestone issued an opinion, stating that claims filed seeking vision monitoring program by the former users of Elmiron residing in the U.S. cannot be litigated as a nationwide class action.

The lawsuit was filed by a plaintiff who was prescribed Elmiron to treat his interstitial cystitis (IC). The plaintiff, on behalf of other IC drug users, whom he seeks to represent as a class, alleged that the defendants negligently failed to conduct adequate safety testing, notify the Federal Drug Administration (FDA) of the link between Elmiron and maculopathy, and alert consumers to the risks of taking the drug.

The plaintiff demanded the defendants to pay for ongoing medical monitoring of prospective class members on the basis that early diagnosis achieved through a monitoring regime will lead to benefits in treatment, management, rehabilitation, or mitigation of long-term health consequences.

The Amended Complaint set forth three separate putative classes: the “Proposed Illinois Class,” the “Proposed Pennsylvania Class,” and “the Proposed Nationwide Class.”

The defendants, Johnson & Johnson (J&J) and its subsidiary Janssen Pharmaceuticals, Inc., filed a motion to strike only "the Proposed Nationwide Class," contending that there are laws in some states, which prevent such medical monitoring claims where there has been no diagnosed injury.

Judge Beetlestone agreed to strike the claims seeking medical monitoring over the medication filed in the Eastern District of Pennsylvania and allowed other claims to proceed in the litigation.

A hearing session is scheduled for December 3, 2020, in San Antonio, Texas, to hear the oral arguments from various parties involved in the lawsuits over the consolidation request filed by a group of plaintiffs asking the U.S. Judicial Panel on Multidistrict Litigation (JPML) to centralize the cases before U.S. District Judge Brian R. Martinotti in New Jersey.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Court Approves $700M Opioid Settlement for Acute Hospitals

Categories: Opioids

A federal court has approved a $700 million class-action settlement that will compensate over 1,000 acute care hospitals for costs related to the opioid crisis.

The settlement consolidates four separate agreements involving major drug…

Philips Settles CPAP Lawsuits Over Toxic Foam for $1.1B

Philips has been embroiled in legal battles following the recall of millions of CPAP, BiPAP, and ventilator devices due to toxic foam degradation.

The breakdown of the foam in these machines may release harmful chemicals, raising serious…

Texas Trial to Decide J&J’s $10B Talcum Powder Settlement

Categories: Talcum

A high-stakes trial in Texas will determine whether Johnson & Johnson (J&J) can resolve tens of thousands of talcum powder cancer lawsuits through a…

🎁 March VIP Medical Record Review Offer – Get 300 Pages Free!         
Includes a Free Life Care Plan Report + 10% Off Future Reviews!

Only 15 Firms Accepted.